Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Enterprise Technology
  • Contract Manufacturing
  • R&D 100 Awards

Pfizer in negotations to provide U.S. another 100M COVID-19 vaccine doses

By Chris Newmarker | December 14, 2020

coronavirus COVID-19 vaccine Pfizer

Image by Markus Winkler on Unsplash

Pfizer CEO Albert Bourla told media outlets today that the company is negotiating a way to speed up the delivery of an additional 100 million doses of its COVID-19 vaccine to the U.S. next year.

Americans are expected to receive some of the first shots of the vaccine today — days after FDA granted an EUA for the Pfizer (NYSE:PFE) and BioNTech (NSDQ:BNTX) vaccine.

Pfizer so far has agreed to provide an initial 100 million doses of the vaccine to the U.S., with each person who receives it requiring two doses. It would likely take until the third quarter of 2021 for Pfizer to provide another 100 million doses for Americans, but Bourla told CNBC that the U.S. government is pushing to get the vaccines by the second quarter.

“We are working very collaboratively to try to find a solution and be able to allocate those 100 million [doses] in the second quarter if possible or a lot of them,” Bourla said. Pfizer doesn’t have an agreement with the U.S. yet.

Bourla told CNN that Pfizer and BioNTech expect to produce 1.3 billion doses of the vaccine over the next year, but 1.2 billion doses are already committed to other countries.

Former FDA commissioner Dr. Scott Gottlieb, a Pfizer board member, used a CNBC appearance to fault the U.S. government for turning down previous Pfizer offers for additional vaccine doses.

President Donald Trump has said he would invoke the Defence Production Act to secure more vaccines for Americans; Bourla thinks such a move would be “very positive” because it would help the company solve supply limitations.

Vaccines from other companies could also soon be on the way. Moderna’s COVID-19 vaccine candidate could receive an authorization as soon as this week, and vaccines from Oxford-AstraZeneca and Johnson & Johnson could win authorizations early next year.

Tell Us What You Think! Cancel reply

Related Articles Read More >

President Joe Biden
Biden to order analysis of pharma supply chain
5 takeaways from the latest White House COVID-19 response team briefing
Pfizer-BioNTech vaccine
Pfizer vaccine stable at standard freezer temps, effective with single dose
Biden
Why Big Tech is offering Biden help with COVID-19 vaccination

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Pharmaceutical Processing news in a minute?

We Deliver!
Pharmaceutical Processing Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup

R&D Twitter

Tweets by @RandDWorld
Pharmaceutical Processing World
  • Enews Signup
  • Contact Us
  • About Us
  • R&D World
  • DeviceTalks
  • Drug Discovery & Development
  • Drug Delivery Business News
  • MassDevice
  • Medical Design Sourcing

Copyright © 2021 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Enterprise Technology
  • Contract Manufacturing
  • R&D 100 Awards